Skip to main content

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

De la sencillez en el diagnóstico (no masivo) y seguimiento de la enfermedad hepática crónica avanzada a los complejos mecanismos terapéuticos de las estatinas en modelos animales.

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Ares Aurora Villagrasa Vilella, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/00947
Duration: 01/01/2019 - 30/06/2023

Enfermedades hepáticas-Enfermedad crónica hepática avanzada y sus complicaciones.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM18/00061
Duration: 01/01/2019 - 20/09/2021

Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Macarena Simon-Talero Horga, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 130075
Reference: PI15/00066
Duration: 01/01/2016 - 31/10/2019

Papel de la elastografía hepática y esplénica en el diagnóstico, seguimiento y tratamiento de la enfermedad crónica hepática avanzada.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI14/00152
Duration: 01/01/2015 - 31/12/2018

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Sebastian Corro  Ramis

Sebastian Corro Ramis

Reconstructive Surgery of the Locomotor System
Read more
Consuelo Garcia Carmona

Consuelo Garcia Carmona

Research technician
Peripheral Nervous System
Read more
Joan Joseph Munné

Joan Joseph Munné

Main researcher
Microbiology
Read more
Juan Ignacio Esteban Mur

Juan Ignacio Esteban Mur

Main researcher
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.